EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals, Inc. to DepoDur®, a Novel Extended-Release Opioid Analgesic for Post Operative Pain

CEDAR KNOLLS, N.J. & SAN DIEGO--(BUSINESS WIRE)--EKR Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, developing, and commercializing proprietary products to enhance patient quality-of-life in the acute care setting, today announced it has acquired exclusive marketing and distribution rights to DepoDur® (morphine sulfate extended release liposome injection) for the Americas from San Diego-based Pacira Pharmaceuticals, who will continue to manufacture the product.